Phase 3
N=332
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Ankylosing Spondylitis
Bottom Line
View on ClinicalTrials.gov: NCT03928743 ↗Enrolled (actual)
332
Serious AEs
4.2%
Results posted
Oct 2024
Primary outcome: Primary: Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16 — 22.5; 44.8 percentage of participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Bimekizumab (Drug); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- UCB Biopharma SRL
- Primary completion
- Sep 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16 |
22.5; 44.8 | <0.001 sig |
| SECONDARY Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Participants at Week 16 |
23.4; 45.7 | <0.001 sig |
| SECONDARY Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16 |
43.2; 66.1 | <0.001 sig |
| SECONDARY Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16 |
-1.70; -2.74 | <0.001 sig |
| SECONDARY Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16 |
7.2; 24.0 | <0.001 sig |
| SECONDARY Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16 |
5.4; 25.8 | <0.001 sig |
| SECONDARY Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16 |
18.9; 49.3 | <0.001 sig |
| SECONDARY Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16 |
-0.95; -2.00 | <0.001 sig |
| SECONDARY Change From Baseline in Nocturnal Spinal Pain Score Numeric Rating Scale (NRS) at Week 16 |
-1.68; -3.16 | <0.001 sig |
| SECONDARY Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16 |
-3.07; -4.59 | <0.001 sig |
| SECONDARY Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16 |
5.17; 8.54 | <0.001 sig |
| SECONDARY Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16 |
-0.17; -0.45 | 0.006 sig |
| SECONDARY Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16 |
-1.04; -2.12 | 0.003 sig |
| SECONDARY Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis Index in the Subgroup of Participants With Enthesitis at Baseline |
32.8; 51.5 | 0.006 sig |
| SECONDARY Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study |
43.2; 54.3; 68.3; 75.8 | — |
| SECONDARY Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study |
0.9; 2.3; 4.7; 6.1 | — |
| SECONDARY Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study |
0; 3.2; 2.8; 4.8 | — |
Summary
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).
Eligibility Criteria
Inclusion Criteria
- Male or female patients at least 18 years of age
- Subject has ankylosing spondylitis (AS) as per the Modified New York (mNY) criteria with documented radiologic evidence, and at least 3 months of symptoms with age at symptom onset less than 45 years
- Subjects has moderate-to-severe active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >=4 AND spinal pain >=4 on a 0 to 10 Numeric Rating Scale
- Subjects had to have either failed to respond to 2 different nonsteroidal anti-inflammatory drugs (NSAIDs) given at the maximum tolerated dose for a total of 4 weeks or have a history of intolerance to or a contraindication to NSAID therapy
- Patients who have taken a tumor necrosis factor alpha (TNFα) inhibitor must have experienced an inadequate response or intolerance to treatment given at an approved dose for at least 12 weeks
- Patients currently taking NSAIDs, cyclooxygenase 2 (COX-2) inhibitors, analgesics, corticosteroids, methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ) AND/OR apremilast can be allowed if they fulfill specific requirements prior to study entry
Exclusion Criteria
- Total ankylosis of the spine
- Treatment with more than 1 TNFα inhibitor and/or more than 2 additional non-TNFα biological response modifiers, or any interleukin (IL)-17 biological response modifier at any time are excluded
- Active infection or history of recent serious infections
- Viral hepatitis B or C or human immunodeficiency virus (HIV) infection
- Any live (includes attenuated) vaccination within the 8 weeks prior to entering the study or TB (Bacillus Calmette-Guerin) vaccination within 1 year prior entering the study
- Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or current or history of nontuberculous mycobacterium (NTMB) infection
- Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma or in situ cervical cancer
- Diagnosis of inflammatory conditions other than AxSpA, eg, rheumatoid arthritis. Patients with a diagnosis of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease (IBD) are allowed as long as they have no active symptomatic disease when entering the study.
- Presence of active suicidal ideation, or moderately severe major depression or severe major depression
- Female patients who are breastfeeding, pregnant, or planning to become pregnant during the study
- Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Data sourced from ClinicalTrials.gov (NCT03928743). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.